Despite "a gap in awareness" among clinicians, Wall Street is focused on the promise of a late-stage experiment with Novavax Inc.'s F-protein respiratory syncytial virus (RSV F) nanoparticle vaccine in elderly people as the company begins another pivotal, phase III study with the drug in pregnant women, Gregory Glenn, senior vice president of R&D, told BioWorld Today.